Sara E Meyer

11PUBLICATIONS
34CO-AUTHORS
Molecular targetsAutoimmunityMedical infection agents (incl. prions)Haematological tumoursCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|May 15, 2026
P300/CBP inhibition with inobrodib in combination with gilteritinib and venetoclax targets leukemia stem cells in epigenetic mutant AML.

|Aug 20, 2025
TLR2 agonism suppresses myeloid leukemogenesis by reprogramming leukemia stem cells.

Michael E Lawler, Jennifer S Romer-Seibert, Michael S Bowman

|Aug 09, 2022
miR-196b-TLR7/8 Signaling Axis Regulates Innate Immune Signaling and Myeloid Maturation in DNMT3A-Mutant AML.

Holly A Gamlen, Jennifer S Romer-Seibert, Michael E Lawler

|Dec 02, 2021
KAT6A and ENL Form an Epigenetic Transcriptional Control Module to Drive Critical Leukemogenic Gene-Expression Programs.

Fangxue Yan, Jinyang Li, Jelena Milosevic

|Oct 29, 2020
Single-cell mutation analysis of clonal evolution in myeloid malignancies.

Linde A Miles, Robert L Bowman, Tiffany R Merlinsky

|Jul 13, 2018
miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential.

Sara E Meyer, David E Muench, Andrew M Rogers

Pageof 2

Frequent Collaborators

3 joint publications

Melanie L Goetz

3 joint publications

Michael E Lawler

3 joint publications

Robert L Bowman

2 joint publications

Amanda M Versace